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Abstract: Dicopper(II) and dizinc(II) complexes [Cu2(
MeOOCLCOO)(CH3COO)2]∙3CH3OH 
(1) and [Zn2(
MeOOCLCOO)(CH3COO)2]∙2CH3OH (2) were synthesized by reaction of 
Cu(CH3COO)2∙H2O and Zn(CH3COO)2∙2H2O with a new nonsymmetric dinucleating 
ligand EtOOCHLCOOEt prepared by condensation of 6-hydrazinyl-11H-indolo[3,2-
c]quinoline with diethyl-2,2´-((3-formyl-2-hydroxy-5-methylbenzyl)azanediyl)diacetate. 
The design and synthesis of this elaborate ligand was performed with the aim of 
increasing the aqueous solubility of indolo[3,3-c]quinolines, known as biologically active 
compounds, and investigating the antiproliferative activity in human cancer cell lines and 
the cellular distribution by exploring the intrinsic fruorescence of indoloquinoline 
scaffold. The compounds have been comprehensively characterized by elemental analysis, 
spectroscopic methods (IR, UVvis, 1H and 13C NMR spectroscopy), ESI mass 
spectrometry, magnetic susceptibility measurements and UV–vis complex formation 
studies (for 1), as well as by X-ray crystallography (1 and 2). The antiproliferative 
activity of  EtOOCHLCOOEt, 1 and 2 was determined by MTT assay in three human cancer 
cell lines, namely, A549 (nonsmall cell lung carcinoma, CH1 (ovarian carcinoma) and 
SW480 (colon adenocarcinoma) yielding IC50 values in the micromolar concentration 
range and showing dependence on the cell line used. The effect of metal coordination on 
cytotoxicity of EtOOCHLCOOEt is also discussed. Subcellular distribution of EtOOCHLCOOEt 
and 2 was investigated by fluorescence microscopy in human cancer cell lines and 
revealed similar localization for both compounds in cytoplasmic structures.   
 
Keywords: nonsymmetrical hybrid ligands, indolo[3,2-c]quinolines, copper(II), zinc(II), 
antiproliferative activity 
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Introduction 
Cancer is a disease difficult to treat and novel drugs are still highly demanded.1–3 Metal 
complexes with biologically active ligands have become increasingly important in the 
development of anticancer drugs, as metal ions can significantly alter their physical and 
biological properties. 4 – 7  Indolo[3,2-d]benzazepines, also referred to as paullones, 
represent a class of potential cyclin-dependent kinase (Cdk) inhibitors, identified in a 
comparative database search at the National Cancer Institute (NCI; NCI60 screen), where 
the lead compound kenpaullone exhibited an activity profile similar to that of 
flavopiridol, 8 , 9  the first clinically tested Cdk inhibitor. Notably, the antiproliferative 
activity of kenpaullone does not parallel its Cdk inhibitory profile. As a result other 
intracellular targets for this class of compounds, e.g. glycogen synthase kinase 3β (Gsk3β) 
or mitochondrial malate dehydrogenase (mMDH), have been suggested.10 Despite the 
directed efforts on their development as anticancer drugs, paullones remain at an early 
preclinical stage mainly because of their low aqueous solubility and bioavailability. Metal 
coordination was suggested as a means to overcome these problems. As original 
paullones did not contain binding sites for metal ions, these were created by chemical 
modification of their molecular structure. A library of paullone-based ligands with a 
broad structural diversity and complexes with copper(II), gallium(III), ruthenium(II) and 
osmium(II) have been reported.11–15 
In an effort to elucidate novel structure–activity relationships (SARs) the folded seven-
membered azepine ring of paullones has been replaced by a pyridine ring leading to 
another class of biologically active compounds, namely indolo[3,2-c]quinolines, with an 
essentially planar structure. Indolo[3,2-c]quinolines and the structurally related 
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indolo[3,2-b]quinolines have been isolated from the roots of the West African climbing 
shrub Cryptolepsis sanguinolenta, used in traditional African medicine. Both exhibit a 
broad spectrum of biological properties, including antibacterial, antitumor, as well as 
anti-inflammatory activity.16 In contrast to indolo[3,2-b]quinolines, only few studies have 
been conducted for indolo[3,2-c]quinolines so far. Like paullones, indoloquinolines do 
not contain binding sites for metal ions. However, these can be introduced by exploring 
chemistry tools essentially different from those applied for paullones. The first 
ruthenium(II), osmium(II) and copper(II) complexes with indolo[3,2-c]quinoline 
modified ligands were derived from structurally related paullone complexes, by using 
distinct chemical transformations, and studies aimed at the discovery of  novel SARs 
have been performed.17–20 In particular, it has been found that indolo[3,2-c]quinolines 
exhibit higher cytotoxicity compared to their paullone-counterparts. In other words the 
effect of replacement of seven-membered azepine ring in paullones by a pyridine ring in 
indoloquinolines has been clearly established. In addition, it was shown that SARs of 
paullone-modified complexes do not necessarily apply to indolo[3,2-c]quinoline-based 
compounds.17,19 Current efforts by us are focused on the investigation of the underlying 
mechanisms of their antiproliferative activity. In this regard, the intrinsic fluorescence of 
indolo[3,2-c]quinolines can also be explored.21   
Recently we published the syntheses of highly antiproliferative copper(II) complexes 
with modified indolo[3,2-c]quinolines.19 Herein we report on the synthesis of a more 
elaborate bioligand with two distinct binding sites, and its dinuclear copper(II) and 
zinc(II) complexes. The new bioconjugate is sufficiently soluble in various biological 
media and intrinsically fluorescent when light-irradiated at λex = 395 nm. These 
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properties permitted us to track the intracellular distribution of the ligand and its zinc(II) 
complex. Moreover, the ligand design led to assembly of homometallic dinuclear 
complexes with distinct compartments (Scheme 1), a feature not explored by us so far in 
the development of anticancer metal complexes. 
 
Scheme 1. Synthesis of EtOOCHLCOOEt, 1 and 2a and atom numbering schemes for 
modified indoloquinolines. 
 
a Reagents and conditions: (i) 35% formaldehyde solution, conc. HCl;22,23 (ii) diethyl-2,2’-iminodiacetate, 
triethylamine, dry THF, room temperature, 3 h (95%); (iii) methanol, room temperature, 2 h (95%); (iv) 
copper(II) acetate monohydrate or zinc(II) acetate dihydrate, methanol, room temperature, 30 min [1 
(37%), 2 (33%)]. 
 
 
Experimental Section 
Materials. All chemicals were purchased from commercial suppliers and were used 
without further purification. Hydrochloric acid, 4-(2-hydroxyethyl)-1-
piperazineethanesulfonic acid (HEPES), 2-hydroxy-5-methylbenzaldehyde (A), diethyl-
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2,2’-iminodiacetate and guanosine 5’-triphosphate were received from Sigma-Alrdich. L-
histidine, formaldehyde solution (35%), copper(II) acetate monohydrate and zinc acetate 
dihydrate from Merck and tetrahydrofuran (THF) and methanol (both analytical reagent 
grade) from Fisher Scientific. THF was dried prior to use by a standard protocol. 
Dimethyl sulfoxide (DMSO) was received from Acros, ammonium bicarbonate, formic 
acid and L-glutamic acid from Fluka and L-aspartic acid from Serva. MilliQ water 
(18.2 MΩ, Millipore Advantage A10, 185 UV Ultrapure Water System, Molsheim, 
France) and methanol (Fisher, HPLC grade) were used for ESI-MS experiments. 6-
Hydrazinyl-11H-indolo[3,2-c]quinolone (D, Scheme 1) was synthesized according to the 
published protocol.18 3-(chloromethyl)-2-hydroxy-5-methylbenzaldehyde (B) was 
obtained from 5-methyl-2-hydroxybenzaldehyde (A) via a previously described 
chloromethylation reaction.22,23  
Diethyl-2,2'-((3-formyl-2-hydroxy-5-methylbenzyl)azanediyl)diacetate (C). To a 
stirred solution of 3-(chloromethyl)-2-hydroxy-5-methylbenzaldehyde (0.100 g, 0.54 
mmol) in dry THF (30 mL) was added diethyl-2,2’-iminodiacetate (85 μL, 0.48 mmol) 
under argon atmosphere. Upon addition of triethylamine (281 µL, 2.0 mmol) the 
colorless solution turned brightly yellow and a white precipitate formed. After stirring for 
3 h at room temperature, the precipitate was filtered off. The yellow filtrate was 
concentrated under reduced pressure to give an orange oil which was dried in vacuo 
overnight. Yield: 0.17 g (95%), 1H NMR 500.13 MHz (DMSO-d6, H, ppm): 10.60 (s, 1H, 
OH), 10.23 (s, 1H, C1), 7.43 (d, 1H, 4J(HC5) = 2.0 Hz, C7), 7.32 (d, 1H,
 4J(HC7) = 2.1 Hz, 
C5), 4.12 (q, 4H, 3J(HC16, C18) = 7.1 Hz, C15, C17), 3.90 (s, 2H, C9), 3.54 (s, 4H, C11, 
C13), 2.26 (s, 3H, C8), 1.20 (t, 6H, 3J(HC15, C17) = 7.1 Hz, C16, C18). 
13C{1H} NMR 
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125.76 MHz (DMSO-d6, C, ppm): 192.9 (C1), 171.2 (C12, C14), 158.3 (C3), 137.9 (C5), 
129.1 (C7), 128.6 (C6), 125.2 (C4), 122.3 (C2), 60.8 (C15, C17), 54.4 (C11, C13), 53.6 
(C9), 20.3 (C8), 14.5 (C16, C18). 
Diethyl-2,2'-((3-(((5H-indolo[3,2-c]quinolin-6(11H)-ylidene)hydrazono)methyl)-2-
hydroxy-5-methylbenzyl)azanediyl)diacetate (EtOOCHLCOOEt). To a solution of C (776 
mg, 2.3 mmol) in methanol (40 mL) was added D (544 mg, 2.2 mmol) The reaction 
mixture turned into a brightly yellow suspension, which was stirred for 2 h under argon 
atmosphere and allowed to stand at 4 °C overnight. The yellow product was filtered off, 
washed with cold methanol (2  4 mL) and dried in vacuo overnight. Yield: 0.77 g, 95%. 
Anal. Calcd for C32H33N5O5·H2O (Mr = 585.65): C, 65.63; H, 6.02; N, 11.96. Found: C, 
65.75; H, 5.85; N, 11.51. 1H NMR 500.13 MHz (DMSO-d6, H, ppm): 12.46 (s, 1H, N11), 
10.72 (s, 1H, N5), 10.63 (s, 1H, OH), 8.77 (s, 1H, C14), 8.43 (d, 1H, 3J(HC8) = 7.8 Hz, 
C7), 8.11 (d, 1H, 3J(HC2) = 7.8 Hz, C1), 7.80 (d, 1H,
 3J(HC3) = 8.3 Hz, C4), 7.61 (d, 1H,
 
3J(HC9) = 8.3 Hz, C10), 7.59 (s, 1H, C20), 7.50 – 7.44 (m, 1H, C3),  7.40 – 7.35 (m, 1H,
 
C9), 7.30 – 7.22 (m, 2H, C8, C2), 7.10 (s, 1H, C18), 4.13 (q, 4H, 3J(HC29, C31) = 7.1 Hz, 
C28, C30), 3.94 (s, 2H, C22), 3.57 (s, 4H, C24, C26), 2.30 (s, 3H, C21), 1.21 (t, 6H, 
3J(HC28, C30) = 7.1 Hz, C29, C31). 
13C{1H} NMR 125.76 MHz (DMSO-d6, C, ppm): 
171.2 (C25, C27), 154.0 (C16), 152.1 (C14), 150.1 (C6), 138.6 (C10a), 138.5 (C11a), 
138.3 (C4a), 132.1 (C18), 129.5 (C3), 129.2 (C20), 127.8 (C19), 124.3 (C9), 124.2 (C17), 
124.1 (C6b), 122.9 (C7), 122.2 (C1), 121.9 (C2), 121.2 (C8), 120.8 (C15), 117.1 (C4), 
113.6 (C11b), 112.0 (C10), 105.2 (C6a), 60.6 (C28, C30), 54.5 (C24, C26), 53.1 (C22), 
20.7 (C21), 14.6 (C29, C31). ESI-MS (methanol), positive: m/z 379 [HL-C8H14NO4]
+, 
568 [EtOOCHLCOOEt + H+]+, 590 [EtOOCHLCOOEt + Na+]+; negative: m/z 566 
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[EtOOCHLCOOEt – H+]–, 603 [EtOOCHLCOOEt + Cl-]–. UV–vis (methanol), lmax (e, M
1 
cm1): 226 (43300), 260 (32350), 273 sh (25300), 306 (22400), 348 (15250), 365 sh 
(15900), 382 (17300). ATR-IR, selected bands, cm1: 3640, 3375, 2976, 1730, 1608, 
1461, 1192, 1002. 
Di(µ-acetato-κ2O,O')-(2-((3-((2-(11H-indolo[3,2-c]quinolin-6-yl-κN5)hydrazono-
κN13)methyl)-5-methyl-2-oxidobenzyl-κO1)(2-methoxy-2-oxoethyl-κO5)amino 
κN23)acetato-κO2)-dicopper(II) (1). To a suspension of EtOOCHLCOOEt (0.200 g, 0.35 
mmol) in methanol (15 mL) was added copper(II) acetate monohydrate (0.157 g, 0.78 
mmol). After stirring for 30 min the dark-green solution was allowed to stand at 25 °C to 
evaporate slowly. After three days, X-ray diffraction quality green crystals formed were 
filtered off, dried in vacuo overnight, and stored under argon atmosphere. Yield: 0.105 g, 
37%. Anal. Calcd for C33H31Cu2N5O9·1.5H2O (Mr = 795.72): C, 49.81; H, 4.31; N, 8.80. 
Found: C, 49.57; H, 4.30; N, 8.64. ESI-MS (methanol), positive: m/z 604 unidentified, 
648 [1 – (HOAc) – (OAc)]+, 680 [1 – (OAc)2 + (CH3O)]
+. UV–vis (methanol), lmax (e, 
M1 cm1): 235 (60800), 272 (41000), 296 (24540), 354 (18900), 420 sh (20800), 441 
(22700). ATR-IR, selected bands, cm1: 1737, 1583, 1540, 1385, 1217, 1028. 
Di(µ-acetato-κ2O,O')-(2-((3-((2-(11H-indolo[3,2-c]quinolin-6-yl-κN5)hydrazono-
κN13)methyl)-5-methyl-2-oxidobenzyl-κO1)(2-methoxy-2-oxoethyl-κO5)amino 
κN23)acetato-κO2)-dizinc(II) (2). To a suspension of EtOOCHLCOOEt (0.140 g, 0.25 mmol) 
in methanol (15 mL) was added zinc acetate dihydrate (0.124 g, 0.57 mmol). After 
stirring for 30 min the yellow solution was allowed to stand at 25 °C to evaporate slowly. 
After four days cold pentane was added and the mixture allowed to stand at 4 °C for 3 h. 
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The yellow precipitate formed was filtered off, dried in vacuo overnight and stored under 
argon atmosphere. Yield: 0.065 g (33%). Anal. Calcd for C33H31N5O9Zn2·CH3OH·H2O 
(Mr = 822.46): C, 49.65; H, 4.53; N, 8.52. Found: C, 49.96; H, 4.35; N, 8.25. 
1H NMR 
500.13 MHz (DMSO-d6, H, ppm): 12.33-11.60 (bs, 2H, N11, N12), 8.62-6.71 (bm, 11H, 
C1-4, 7-10, 14, 18, 20), 4.00-3.53 (bm, 9H, C22, 24, 26, 28), 2.22 (s, 3H, C21), 1.88 (bs, 
6H, CH3COO). ESI-MS (methanol), positive: m/z 668 [2 – (OAc)2 – (CH3) + (CH3OH)]
+, 
682 [2– (OAc)2 + (CH3O)]
+, 710 [2 – (OAc)]+, 724 unidentified, 784 unidentified. UV–
vis (methanol), lmax (e, M
1 cm1): 230 (44400), 258 (45700), 290 (27900), 309 (31000), 
330 (17900), 346 (18200), 394 (18900). ATR-IR, selected bands, cm1: 1744, 1706, 1583, 
1407, 1216, 1012. X–ray diffraction quality crystals were picked from the reaction vessel 
prior to addition of pentane. 
Physical Measurements and Instrumentation. 1H, 13C and two-dimensional 1H-1H 
COSY, 1H-1H TOCSY, 1H-13C HSQC and 1H-13C HMBC NMR spectra were recorded on 
a Bruker Avance III spectrometer (Ultrashield Magnet) in DMSO-d6 at 25 °C using 
standard pulse programs at 500.13 (1H) and 125.76 (13C) MHz. 1H and 13C NMR 
chemical shifts are quoted relative to the residual solvent signals. Elemental analyses 
were carried out at the Microanalytical Service of the Faculty of Chemistry of the 
University of Vienna. Electrospray ionization mass spectrometry was performed on a 
Bruker Esquire 3000 instrument (Bruker Daltonic, Bremen, Germany) on samples 
dissolved in methanol. UV–vis spectra were recorded with an Agilent 8453 
spectrophotometer in the 190 to 1000 nm window, using samples dissolved in methanol 
at 10 µM concentrations. IR spectra were measured with a Bruker Vertex 70 Fourier 
transform IR spectrometer by means of the attenuated total reflection (ATR) technique. 
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Fluorescence excitation and emission spectra were recorded with a Horiba FloroMax-4 
spectrofluorimeter and processed using the FluorEssence v3.5 software package. Samples 
of EtOOCHLCOOEt and 2 were prepared from a 1 mM solution of each in DMSO and 
dilution with HEPES buffer (20 mM, pH = 7.4) to give samples at 10 µM concentrations 
with a maximum content of 1% DMSO (v/v). 
Crystallographic Structure Determination. X-ray diffraction measurements were 
performed on a Bruker X8 APEXII CCD diffractometer. Single crystals were positioned 
at 40 mm from the detector, and 1312 and 722 frames were measured, each for 60 and 
90 s over 1° scan width for 1·3CH3OH and 2·2CH3OH, correspondingly. The data were 
processed using SAINT software.24 Crystal data, data collection parameters, and structure 
refinement details are given in Table 1. The structures were solved by direct methods and 
refined by full-matrix least-squares techniques. Non-H atoms were refined with 
anisotropic displacement parameters, while H atoms were inserted in calculated positions 
and refined with a riding model. The following software programs were used: structure 
solution, SHELXS-97; refinement, SHELXL-97; 25  molecular diagrams, ORTEP; 26 
computer, Intel CoreDuo. 
Table 1. Crystal data and details of data collection for 1∙3CH3OH and 2∙2CH3OH. 
 1·3CH3OH 2·2CH3OH 
empirical formula  C36H43Cu2N5O12 C35H39N5O11OZn2 
fw 864.83 836.45 
space group P−1 P−1 
a [Å] 11.1929(5) 10.7024(5) 
b [Å] 11.3582(5) 11.6277(5) 
c [Å] 15.4454(7) 15.4646(8) 
 [°] 71.745(2) 99.404(3) 
 [°] 76.682(3) 105.532(3) 
 [°] 81.086(2) 94.840(3) 
V [Å3] 1807.32(14) 1812.59(15) 
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Z 2 2 
l [Å] 0.71073 0.71073 
calcd [g cm
-3] 1.589 1.533 
crystal size [mm3] 0.20  0.10  0.02 0.15  0.15  0.10 
T [K] 120(2) 120(2) 
 [mm-1] 1.249 1.533 
R1
[a] 0.0418 0.0485 
wR2
[b] 0.1242 0.1420 
GOF[c] 1.071 1.084 
a R1 = ||Fo|  |Fc||/|Fo|. 
b wR2 = {[w(Fo
2  Fc
2)2]/[w(Fo
2)2]}1/2. c GOF = {[w(Fo
2  Fc
2)2]/(n  p)}1/2, 
where n is the number of reflections and p is the total number of parameters refined.  
 
Magnetic Studies. Magnetic measurements were carried out on a microcrystalline 
sample of 1 with a Quantum Design SQUID magnetometer (MPMS-XL). Variable-
temperature (2300 K) direct current (dc) magnetic susceptibility was measured under an 
applied magnetic field of 0.1 T. All data were corrected for the contribution of the sample 
holder and diamagnetism of the samples estimated from Pascal’s constants. 27 , 28  The 
analysis of the magnetic data was carried out by fitting the χMT(T) and χM(T) thermal 
variations including temperature independent paramagnetism (TIP), impurity contribution 
(ρ), and intermolecular interaction (zJ’)28,29,30 according to the expression:  
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UV–vis Titration Studies. Complex formation was studied by UV–vis titration of 10 and 
250 µM solutions of EtOOCHLCOOEt in methanol with 10 µL aliquotes of 0.5 mM and 6.25 
mM stock solutions of copper(II) acetate monohydrate, respectively. One aliquote was 
added at 2 min intervals followed by the homogenization of the solutions as within this 
period the equilibrium could be reached. An Agilent 8453 spectrophotometer  was used 
to record the UV–vis spectra in the 190 to 1000 nm window. The path length was 1 cm. 
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Stability constants and the molar absorbance spectra of the individual copper(II) 
complexes were calculated by the computer program PSEQUAD.31 
ESI–MS Studies. Electrospray ionization mass spectra were recorded on an AmaZon SL 
ion trap mass spectrometer (Bruker Daltonics GmbH, Bremen, Germany). Experimental 
data was acquired using Compass 1.3 software and processed using Data Analysis 4.0 
(Bruker Daltonics GmbH, Bremen, Germany). The experimentally obtained mass signals 
include a standard deviation of m/z ± 0.06. The general instrument parameters were set as 
follows: Positive ion mode (HV –4.5 kV, RF level 89%, trap drive 74.4, dry temperature 
250 °C, nebulizer 8 psi, dry gas 6 L/min and average accumulation time 144 µs), negative 
ion mode (HV 4.5 kV, RF level 89%, trap drive 63.8, dry temperature 250 °C, nebulizer 
8 psi, dry gas 6 L/min and average accumulation time 2 ms). The samples were diluted 
with water : methanol (50 : 50) or water : methanol : formic acid (50 : 50 : 0.2) to a final 
metal concentration of 5–10 µM and measured by direct infusion into the mass 
spectrometer at a flow rate of 4 µL/min. Stock solutions of 1 and 2 in DMSO (10 mM) 
were prepared and stored at –20 °C in the dark. Each compound was diluted in 
ammonium carbonate buffer (20 mM, pH = 6) to give a solution of 100 µM of each 
compound (with 1% DMSO content). Furthermore, a solution containing L-histidine 
(His), L-aspartic acid (Asp), L-glutamic acid (Glu) and guanosine 5’-triphosphate (GTP) 
in equimolar amounts (100 µM each) and a solution containing His, Asp, Glu, GTP (each 
100 µM) and ascorbic acid (Asc, 400 µM) were prepared in the same buffer. The metal-
containing solutions were diluted with buffer or mixed with the solutions containing the 
amino acids and Asc at equimolar ratios to give a final metal concentration in each 
incubation mixture of 50 µM. The reaction mixtures were incubated at 37 °C and aliquots 
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were measured directly after mixing and after 1, 3, 5 and 24 h. Detection of 1 and 2 in 
electrospray ionization mass spectrometry (ESI MS) experiments required dilution with 
water : methanol (1 : 1) and incubation in ammonium carbonate (20 mM, pH = 7.95). The 
slightly acidic ammonium acetate buffer (20 mM, pH = 6) was avoided, because it lead to 
partial metal release. Dilution with water resulted in a low ionization in the positive and 
negative ion modes. 
 
Cell Lines and Cell Culture Conditions. For cytotoxicity determination, three different 
human cancer cell lines were used: A549 (non-small cell lung cancer) and SW480 (colon 
carcinoma) (both kindly provided by Brigitte Marian, Institute of Cancer Research, 
Department of Medicine I, Medical University Vienna, Austria) as well as CH1 (ovarian 
carcinoma) (kindly provided by Lloyd R. Kelland, CRC Centre for Cancer Therapeutics, 
Institute of Cancer Research, Sutton, U.K.). Cells were grown as adherent monolayer 
cultures in 75 cm² culture flasks (StarLab, CytoOne) in Minimal Essential Medium 
supplemented with 10% heat-inactivated fetal bovine serum, 1 mM sodium pyruvate, 1% 
v/v non-essential amino acids (from 100× ready-to-use stock) and 4 mM L-glutamine but 
without antibiotics at 37 °C under a moist atmosphere containing 5% CO2 and 95% air. 
All cell culture media and reagents were purchased from Sigma-Aldrich Austria. 
 
Cytotoxicity Assay. Cytotoxicity was determined by the colorimetric MTT assay (MTT 
= 3-(4,5-dimethyl-2-thiazolyl)-2,5-diphenyl-2H-tetrazolium bromide) as described 
previously.19 Briefly, cells were harvested by trypsinisation and seeded in medium (vide 
supra) into 96-well plates in volumes of 100 μL/well. Depending on the cell line, 
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different cell densities were used to ensure exponential growth of the untreated controls 
during the experiment: 1.0 × 103 (CH1), 2.0 × 103 (SW480), 3.0 × 103 (A549) cells per 
well. In the first 24 h the cells were allowed to settle and resume exponential growth. 
Then the test compounds were dissolved in DMSO, serially diluted in medium and added 
to the plates in volumes of 100 μL/well so that the DMSO content did not exceed 1%. 
Due to limited solubility of EtOOCHLCOOEt and 1, the medium in the wells used for the 
highest concentrations was replaced with 200 µL/well of medium containing the test 
compounds. After continuous exposure for 96 h (in the incubator at 37 °C and under 5% 
CO2), the medium was replaced with 100 μL/well RPMI 1640 medium (supplemented 
with 10% heat-inactivated fetal bovine serum and 4 mM L-glutamine) and MTT solution 
(MTT reagent in phosphate-buffered saline, 5 mg/mL) in a ratio of 7:1, and plates were 
incubated for further 4 h. Then the medium/MTT mixture was removed and the formed 
formazan was dissolved in DMSO (150 μL/well). Optical densities at 550 nm were 
measured (reference wavelength: 690 nm) with a microplate reader (ELX880, BioTek). 
The quantity of viable cells was expressed as a percentage of untreated controls, and 50% 
inhibitory concentrations (IC50) were calculated from the concentration-effect curves by 
interpolation. Every test was repeated in at least three independent experiments, each 
consisting of three replicates per concentration level. 
 
Fluorescence microscopy. SW480, A549 and CH1 cells were seeded in medium on 
cover slips in 6-well plates and allowed to settle and resume exponential growth for 24 h. 
Then cell were incubated for 1–2 h with 5 µM of 2 or 10 µM of EtOOCHLCOOEt, in 
medium. Co-staining with ER-Tracker Red and Lyso-Tracker Red (Invitrogen) was 
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performed according to the manufacturer’s instructions. After staining, each slide was 
washed three times in PBS. A fluorescence microscope BX40 (Olympus) with F-View 
CCD Camera (Olympus), Cell^F fluorescence imaging software (Olympus) and 60 
magnification oil immersions objective lens were used. 
 
Results and Discussion 
Synthesis and Characterization. The syntheses of the ligand EtOOCHLCOOEt and 
copper(II) and zinc(II) complexes 1 and 2, respectively, were carried out as shown in 
Scheme 1. We prepared a potentially hexadentate nonsymmetric ligand consisting of two 
chelating arms, one able to provide a facial coordination to an octahedral metal ion, while 
the second exhibits a meridional binding mode. Ester functionalities are frequently 
introduced into the structure of organic molecules to improve their aqueous solubility and 
bioavailability.32 
Recently, our group reported on the conjugation of L- and/or D-proline to 3-
(chloromethyl)-2-hydroxy-5-methylbenzaldehyde (B), after chloromethylation of 2-
hydroxy-5-methylbenzaldehyde (A) (Scheme 1). 33  Similarly, we reacted 3-
(chloromethyl)-2-hydroxy-5-methylbenzaldehyde (B) with diethyl-2,2’-iminodiacetate 
and triethylamine in dry THF at room temperature yielding diethyl-2,2'-((3-formyl-2-
hydroxy-5-methylbenzyl)azanediyl)-diacetate (C) as an orange oil in excellent yield 
(95%). The ligand EtOOCHLCOOEt was obtained by reacting C with 6-hydrazinyl-11H-
indolo[3,2-c]quinoline (D)18 in methanol at room temperature, again in excellent yield 
(95%). Complexes 1 and 2 were synthesized in 37 and 33% yields starting from the 
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ligand EtOOCHLCOOEt and copper(II) acetate monohydrate, and/or zinc(II) acetate 
dihydrate, respectively, in methanol at room temperature. Complexation reaction in both 
cases is accompanied by hydrolysis of one ethyl ester group and transesterification of 
another ethyl ester function with formation of a new ligand MeOOCHLCOOH. Both 
generated donor arms are involved in coordination to copper(II) and zinc(II) in 1 and 2, 
respectively, via the deprotonated carboxylate group and the carbonyl oxygen of the 
methyl ester group (see Scheme 1, Figures 1 and 2). 
The new ligand EtOOCHLCOOEt and its zinc(II) complex 2 have been characterized by one- 
and two-dimensional NMR spectroscopy, ESI mass spectrometry, elemental analysis, 
UV–vis and ATR-IR spectroscopy, while copper(II) complex 1 by magnetic 
susceptibility measurements, ESI mass spectrometry and optical spectroscopy. 
Additionally, both complexes have been characterized by X-ray crystallography. 
The 1H and 13C NMR spectral data of intermediate C, ligand EtOOCHLCOOEt and zinc(II) 
complex 2 along with their assignments are given in the Experimental Section. The 
presence of a proton at N5 in the 1H NMR spectra and the chemical shift of neighboring 
C6 in the 13C NMR spectra indicate that the ligand adopts a configuration with an 
exocyclic C6=N12 double bond. ESI mass spectra of 1 and 2 in methanol showed peaks 
that confirmed the formation of dimetal complexes. The most abundant peaks at m/z 680 
and 682 for 1 and 2, correspondingly, were assigned to [1/2 – (OAc)2 + (CH3O)]
+. 
The UV–vis spectra of EtOOCHLCOOEt and 1 and 2 in methanol are depicted in Figure S1 
(Supporting Information). Metal coordination led to pronounced changes in the visible 
range of the ligand spectrum, namely to an evolution of an absorption band at ca. 400 nm 
for 2 and the formation of a broad charge–transfer band at 440 nm for 1.  
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X-ray crystallography. The results of X-ray diffraction studies of 1·3CH3OH and 
2·2CH3OH shown in Figures 1 and 2, respectively confirm the formation of dinuclear 
complexes with the two copper(II) ions and zinc(II) ions bridged by the phenolate oxygen 
and two exogenous µ2-
1:1 acetato ligands.34 Both copper(II) ions in 1 are distorted 
square-pyramidal, with  = 0.2735 for Cu1 with the bridging phenolate oxygen O1 in 
apical position, and tertiary amine N23, atoms O6 and O8 of the two bridging acetates 
and one aminoacetate O2 in the basal plane. We do not describe the coordination 
environment around Cu1 as octahedral, since the interaction between Cu1 and O5 of the 
dangling methyl ester group is extremely weak (Cu1∙∙∙O5 2.946(2) Å). For Cu2 a 
distorted square-pyramidal coordination geometry ( = 0.22) was realized with a bridging 
phenolate oxygen O1, quinoline nitrogen N5, hydrazinic nitrogen N13 and one oxygen 
atom O9 of bridging acetate in a basal plane, and another bridging acetate oxygen atom 
O7 in apical position.  
Unlike 1, the coordination environments of zinc(II) ions in 2 differ from each other. Zn1 
has an octahedral environment built up by the bridging phenolate oxygen O1, tertiary 
amine donor N23, methyl ester oxygen O5 and atom O6 of the bridging acetate in 
equatorial positions and two oxygen atoms, one aminoacetate O2 and second O8 of 
abridging acetate in apical positions. Zn2 in contrast to Cu2 shows a more pronounced 
tendency towards a trigonal-bypyramidal coordination geometry ( = 0.47) of the same 
donor atoms. Cu2 lies in the mean plane through Cu2N5C6N12N13 in 1, while Cu1 
comes out from this plane by 1.307 Å. In 2 the deviation of Zn1 from the mean plane 
through Zn2N5C6N12N13 is markedly smaller (0.820 Å), while distortion from planarity 
of the indoloquinoline moiety is more evident than in 1. The bridging of copper(II) ions 
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via phenolate oxygen results in distinct Cu1O1 and Cu2O1 bond distances. The 
difference between them (0.39 Å) is larger than in other nonsymmetrically µ-phenoxido 
bridged dicopper(II) complexes, in which the two copper(II) ions in addition are bridged 
by at least one exogenous µ2-
1:1 acetato group.36,37 The Cu1O6 bond distance is 
markedly shorter than Cu2O7, and Cu1O8 is also shorter than Cu2O9 (see caption to 
Figure 1). The Cu1∙∙∙Cu2 distance in the complex is at 3.2897(6) Å, which is comparable 
with Cu∙∙∙Cu distances of 3.297(3) Å38 and 3.263(2) Å39 in dicopper(II) complexes with 
symmetric dinucleating ligands, containing a di-µ-acetato-µ-phenolato-dicopper(II) core.  
 
Figure 1. ORTEP view of [Cu2(
MeOOCLCOO)(CH3COO)2] with thermal ellipsoids drawn 
at 50% probability level. Selected bond distances (Å) and bond angles (deg): Cu1−O1 
2.323(2), Cu1−O2 1.937(2), Cu1−O6 1.946(2), Cu1−O8 1.936(2), Cu1−N23 2.093(3), 
Cu1···O5 2.946(2), Cu2−O1 1.913(2), Cu2−O7 2.194(2), Cu2−O9 2.002(2), Cu2−N5 
2.038(3), Zn2−N13 1.956(3), Cu1−O1−Cu2 101.47(10).  
 
The Zn1O1 bond distance is only slightly longer than Zn2O1 as also observed in other 
complexes with nonsymmetrical dinucleating ligands with a di-µ-acetato-µ-phenolato-
dizinc(II) core.40  The Zn1O6 bond distance is only slightly longer than Zn2O7, while 
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the difference between Zn1O8 and the shorter bond Zn2O9 is more pronounced (see 
caption to Figure 2). The interaction between Zn1 and O5 of the dangling methyl ester 
group is markedly stronger than comparable interaction in 1. The Zn1∙∙∙Zn2 distance in 
the complex is at 3.2154(7) Å, which is similar with Zn∙∙∙Zn distance of 3.29(1) Å40a in 
dizinc(II) complex with a nonsymmetrical hybrid ligand.  
 
 
 
 
Figure 2. ORTEP view of [Zn2(
MeOOCLCOO)(CH3COO)2] with thermal ellipsoids drawn 
at 50% probability level. Selected bond distances (Å) and bond angles (deg): Zn1−O1 
2.057(3), Zn1−O2 2.105(3), Zn1−O6 2.004(3), Zn1−O8 2.079(3), Zn1−N23 2.149(4), 
Zn1−O5 2.322(3), Zn2−O1 2.027(3), Zn2−O7 1.991(3), Zn2−O9 1.993(3), Zn2−N5 
2.087(4), Zn2−N13 2.097(4), Zn1−O1−Zn2 103.86(14). 
 
Magnetic properties. The magnetic behavior of a polycrystalline sample of 1∙3CH3OH 
in the temperature range 2300 K in a field of 0.1 T is shown in Figure 3. The value of 
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χMT is 0.952 cm
3 K mol−1 at 300 K. This value is slightly higher than the expected χMT 
value (0.750 cm3 K mol−1) for two noninteracting copper(II) ions (d9, g = 2.0, S = ½). The 
value of χMT continuously increases with decreasing temperature and reaches a value of 
1.174 cm3 K mol−1 at 3 K. This behavior suggests the presence of ferromagnetic 
interactions in 1∙3CH3OH. According to X-ray diffraction data complex 1∙3CH3OH has a 
dinuclear structure, in which the two copper(II) ions are connected by a phenolate oxygen 
atom and two bidentate briging acetate groups (Figure 1). Therefore, the magnetic 
behavior can be analysed by using the classical spin Hamiltonian:28,29,41 
H = −2JS1S2 
where J is the exchange coupling constant and S1 = S2 = ½.  
In this case, the Van Vleck equation leads to the following analytical expression: 
TkJ
B
Cu
d
BeTk
ßNg
/2
22
3
12

  
The fitting procedure results in an excellent agreement between the experimental data and 
the calculated curve (R= 1.4 × 106; Figure 3). The parameters extracted from the fit are J 
= 3.49(3) cm1, g = 2.24(1), and zJ = 0.08(1) cm1 and correspond to ferromagnetic 
interaction between copper(II) ions. The temperature independent paramagnetism (TIP) 
and impurity contribution (ρ) take values close to zero and, both were fixed at zero in the 
final fit. The presence of ferromagnetic interaction was confirmed by magnetization 
measurements at low temperature (see inset picture in Figure 3). The fitting of 
magnetization vs. field by using the Brillouin function indicates the presence of spin 
ground state S = 1 (g = 2.203(2)) in 1∙3CH3OH, which is consistent with the results 
obtained from the analysis of the temperature dependence of magnetic susceptibility. 
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Figure 3. The plots of χMT vs T and magnetization vs. H (inset) at 2 and 3K for 
1∙3CH3OH. The solid lines correspond to the best fit with parameters quoted in the text. 
 
The nature of magnetic interaction in dinuclear copper(II) complexes has been 
extensively studied from both theoretical and experimental points of 
view.42,43,44,45,46,47,48,49,50 The magnetic interaction in 1∙3CH3OH occurs via three bridges: 
two µ2-
1:1 acetato ligands and one bridging phenolate.  
Cu1
Cu2
Cu1
Cu2
φ
α
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Figure 4. The coordination core in 1∙3CH3OH showing the angles α and φ. 
 
According to the literature46 the acetate bridges mediate the antiferromagnetic 
interactions, while the phenolate bridge in dinuclear copper(II) complexes can promote  
both antiferromagnetic, as well as ferromagnetic interactions. The character of magnetic 
interaction depends on geometrical features, and, especially on the CuOCu angle α, 
out-of-plane deviation angle φ (see Figure S4) and the torsion angle CuOCuO. For α 
angles <99o and φ angles >30o, a strong ferromagnetic interaction can be expected.46 In 
the case of 1∙3CH3OH with α = 101.47
 o and φ = 30.04o, the presence of a weak 
ferromagnetic interaction (J = 3.49 cm1) is justified. We can conclude that due to the 
out-of-plane deviation of the phenol group relative to CuOCu plane the resulting 
magnetic interaction between the triple bridged Cu(II) ions is weekly ferromagnetic. 
Comparable weekly ferromagnetic interactions were reported for other dinuclear 
copper(II) dinuclear complexes with two49,51 or three different bridges.50,52,53,54,55,56  
 
Complex Formation Studies. To elucidate whether the two binding sites in 
EtOOCHLCOOEt show different affinities to copper(II), complex formation was studied for 
1 via UV–vis titrations of the ligand EtOOCHLCOOEt at two different concentrations with 
copper(II) acetate hydrate in methanol at room temperature (Figures 4 and 5). 
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Figure 4. UVvis absorbance spectrum of the ligand EtOOCHLCOOEt (dashed trace) and its 
changes by the addition of copper(II) acetate monohydrate (solid traces) in methanol (cL 
= 10 µM; cCu = 0 – 22.5 µM; T = 298 K; l = 1 cm). Inset shows the calculated molar 
absorption spectra of the copper(II) complexes. 
 
 
Figure 5. UVvis absorbance spectrum of the ligand EtOOCHLCOOEt (dashed trace) and its 
changes by the addition of copper(II) (solid traces) in methanol (cL = 250 µM; cCu = 0 – 
562.5 µM; T = 298 K; l = 1 cm).  
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The development of a broad charge-transfer band at ca. 440 nm was observed upon 
addition of up to ~1.5 molar equivalents of copper(II). Then a small shift of the λmax 
occurred (Figure 4). Characteristic spectral changes have also been registered in the range 
of the d-d transitions (Figure 5). A wide band with λmax at 664 nm overlapped partly with 
the charge-transfer band was seen upon addition of copper(II). This absorption band is 
slightly red-shifted upon addition of more than 1 equiv of copper(II). Based on the 
spectral changes in the wavelength range 230 – 520 nm (Figure 5) overall stability 
constants have been calculated for the mono- [CuL] (logβ = 7.17 ± 0.08) and dinuclear 
[Cu2L] species (logβ =  13.13 ± 0.24; logK = 5.96). The molar absorbance spectra of the 
ligand, [CuL] and [Cu2L] complexes were also calculated (Figure 4). The goodness-of-fit 
between measured and calculated absorbance values is shown in Figure 6. Stability 
constants obtained by using the changes of the d-d transition bands were in a good 
agreement with those obtained by monitoring the charge-transfer band within 0.2 log 
unit. The stepwise formation constant of the [Cu2L] species is merely ~1 log unit lower 
than that of the [CuL] showing the overlapping binding of the metal ions. Therefore it can 
be concluded that both binding sites in ligand EtOOCHLCOOEt coordinate with a similar 
affinity and no preference for either one can be perceived. 
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Figure 6. The measured and calculated (dashed lines) absorbance values at 382 nm (♦) 
and 440 nm (×) at various EtOOCHLCOOEt -to-copper(II) ratios (cL = 10 µM; cCu = 0 – 22.5 
µM; T = 298 K; l = 1 cm, methanol).  
 
ESI-MS Studies. The stability of complexes 1 and 2 in aqueous solution and their 
reactivity towards small biomolecules was studied by ESI mass spectrometry. Both 
complexes display a very similar aqueous solution behavior, which is characterized by 
ester hydrolysis of the ligand and partial metal release over time. Products of ester 
hydrolysis are detected directly after dissolving the compounds in buffer and the ester is 
quantitatively hydrolyzed within 24 h. The major thermodynamic products after 24 h 
correspond to ions [M2(L–CH3)(OH) – H
+]– and [M(L–CH3) – H
+]–, where M = Cu or Zn 
and L = MeOOCLCOO detected in the negative ion mode (Figure 7). The latter mass signal 
suggests that release of specifically one metal can occur from both 1 and 2. Interestingly, 
these signals are detected at 95% and 38% intensities relative to [M2(L–CH3)(OH) – H
+]- 
for 1 and 2, respectively, i.e. the Cu-complex 1 releases one metal-equivalent to a greater 
extent. Therefore, complex 2 appears to be slightly more stable in aqueous solution. 
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Additionally, 2 does not ionize in the positive ion mode, suggesting stable bonds between 
Zn ions and the acetate ligands (Figure S2). Note that acetato-complexes were not 
detected at all in the mass spectra of 1 or 2. Furthermore, the isotopic distributions of the 
mass signals of 2 indicate the formation of redox couples (Figure S3). Both complexes 
were exposed to mixtures containing equimolar amounts of His, Asp, Glu and GTP. The 
complexes did not react with any of the biological nucleophiles and similar mass spectra 
were observed compared to the solutions containing only the respective metal. Addition 
of 4 equiv of Asc to the amino acids resulted in the transient formation of Glu- and Asc-
adducts with 1 in a small amount, however, they were only detected immediately after 
mixing (Figure 7, C) and were absent for 2. Free ascorbate was consumed within 1 h, but 
had no impact on the overall reactivity of the complexes. An interesting feature of both 
compounds is their ability to release a metal ion in a pH-dependent manner (Figure S4). 
The samples incubated for 24 h displayed only partial metal-release. Lowering the pH of 
this incubation solution with formic acid resulted in the immediate and quantitative 
release of one metal from both dimetallic complexes. It is suggested that the carboxylates 
are prone to protonation under these conditions, leading to the release of the octahedral 
coordinated metal.  
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Figure 7. The ESI mass spectra in the negative ion mode are shown for 1 (A) and 2 (B). 
The istotopic distributions of the most abundant mass signals are shown on the right. The 
isotopic pattern of [Zn2(L–CH3)(OH) – 2H
+]+ seems to involve redox couples. 
Simulations are shown in grey. The Glu- and Asc-adducts of 1 are displayed in (C) 
directly after mixing. 
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Fluorescence Properties. Fluorescence spectra of EtOOCHLCOOEt and 2 were recorded in 
HEPES buffered solutions (20 mM; pH = 7.4) with a 1% v/v content of DMSO (Figure 
8). Fluorescence excitation spectra (λem = 470 nm) were measured in the range between 
260 and 460 nm and emission spectra (λex = 395 nm) in the range from 410 to 710 nm. 
The emission maximum of the ligand was observed at 532 nm. Coordination to zinc(II) 
led to a blue-shift of the emission band by 54 nm, with the maximum at 466 nm in the 
spectra of 2. EtOOCHLCOOEt was found fluorogenic, as excitation and emission spectra 
strongly increased in intensity upon binding to zinc(II).  
 
Figure 8: Fluorescence excitation (λem = 470 nm) and emission (λex = 395 nm) spectra of 
10 µM solutions of EtOOCHLCOOEt (dashed traces) and 2 (solid traces) at physiological pH 
(20 mM HEPES buffer,  1% v/v DMSO). 
 
Cytotoxicity in Cancer Cells. The cytotoxicity of EtOOCHLCOOEt, 1 and 2 was 
determined by the MTT assay in three human cancer cell lines, namely, A549 (non-small 
cell lung carcinoma), CH1 (ovarian carcinoma) and SW480 (colon adenocarcinoma), all 
yielding IC50 values in the micromolar concentration range (Table 2). 
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Table 2. Cytotoxicity of ligand EtOOCHLCOOEt, complexes 1 and 2 in three human cancer 
cell lines.  
 
 IC50 (µM), 96 h
a 
  EtOOCHLCOOEt 1 2 
A549 28 ± 2 30 ± 4 12 ± 1 
CH1 2.2 ± 0.3 6.6 ± 1.3 1.6 ± 0.4 
SW480 16 ± 2 22 ± 2 7.8 ± 0.3 
 
a50% inhibitory concentrations (means ± standard deviations from at least three independent 
experiments), as obtained by the MTT assay using exposure times of 96 h. 
 
CH1 was the most sensitive cell line to all tested compounds, whereas A549, a more 
chemoresistant cell line, was the least sensitive one. In CH1 cells the compounds were up 
to 12 times more potent than in A549 cells. Whereas complexation with copper(II) has 
either little effect on cytotoxicity (A549, SW480 cells) or yields 3-fold decreased potency 
(CH1 cells), complexation with zinc(II) results in about twofold enhancement of 
cytotoxicity, in all three cell lines, compared to the metal free ligand EtOOCHLCOOEt. In 
comparison to the dicopper(II) complex 1, the dizinc(II) complex 2 is up to three times 
more active in SW480 and four times more active in CH1 cells (see also Figure 7). Based 
on these observations, it can be concluded that complexation to zinc(II) results in higher 
cytoxicity and better solubility in biocompatible media compared to both the metal-free 
ligand and copper(II) complex 1.  
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Figure 7. Concentration-effect curves of EtOOCHLCOOEt, complexes 1 and 2, in the 
human cancer cell lines A549 (A), CH1 (B) and SW480 (C), determined by the MTT 
assay using continuous exposure for 96 h. 
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Fluorescence Microscopy. Based on the fluorescence properties of EtOOCHLCOOEt and 
dizinc(II) complex 2, their subcellular localization was studied by fluorescence 
microscopy in human cancer cells including their co-localization with organelle-specific 
dyes. For visualization of the compounds in live SW480, A549 and CH1 cells the U-
MG2 (Olympus Japan) filter was used, while the co-staining dyes were recorded using 
the U-MGU2 (Olympus Japan) filter. The compounds do not show interference in the U-
MGU2 channel and auto-fluorescence of the cells was not observed with the used filters. 
The microscopic images of EtOOCHLCOOEt and 2, as shown in Figure 8, revealed 
localization of the compounds in cytoplasmic structures. The highest accumulation of the 
compounds matches with both the ER-Tracker Red and Lyso-Tracker Red staining, 
suggesting that the endoplasmic reticulum as well as the lysosomes can be potential 
targets of these compounds or that lysosomes are involved in sequestration and/or 
detoxification of the compounds.  
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Figure 8. Fluorescence microscopy images of live SW480 cells. Cells were co-stained 
with 10 µM of EtOOCHLCOOEt (A) or 5 µM of 2 (B) and ER-Tracker Red (500 nM) and 
Lyso-Tracker Red (1 µM), respectively. Magnification of areas marked by squares, are 
shown as insets. Scale bars are 20 µm. 
 
Conclusion 
Condensation of 6-hydrazinyl-11H-indolo[3,2-c]quinoline with diethyl-2,2´-((3-formyl-
2-hydroxy-5-methylbenzyl)azanediyl)diacetate afforded a new nonsymmetric 
dinucleating ligand EtOOCHLCOOEt with increased aqueous solubility and fluorescence 
properties. In the presence of 2 equiv Cu(CH3COO)2∙H2O and Zn(CH3COO)2∙2H2O in 
methanol complexes 1 and 2 are formed. Complexation reaction in both cases is 
accompanied by hydrolysis of one ethyl ester group and transesterification of another 
ethyl ester function with formation of MeOOCHLCOOH. Dinuclear structure in 1∙3CH3OH 
and 2∙3CH3OH is supported by three bridges: two acetato ligands and one phenolate 
bridge from nonsymmetric MeOOCHLCOOH ligand. The temperature dependence and field 
dependence magnetic measurements for 1∙3CH3OH indicate a weak ferromagnetic 
interaction (J = 3.49 cm1) between copper(II) ions. All three compounds show 
respectable antiproliferative activity in human cancer cell lines (A549, CH1, SW480) 
with IC50 values in the micromolar concentration range. Localization of 
EtOOCHLCOOEt 
and 2 in cytoplasmic structures has been found by fluorescence microscopy, suggesting 
that the endoplasmic reticulum as well as the lysosomes can be potential targets of these 
compounds. 
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Supporting Information 
Further details are given in Figures S1-S4 and Table S1, and crystallographic data is 
given in CIF format. 
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